6.
  
    Bustamante J, Aksu G, Vogt G, de Beaucoudrey L, Genel F, Chapgier A
    
    . BCG-osis and tuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol. 2007; 120(1):32-8.
    
          DOI: 10.1016/j.jaci.2007.04.034.
    
    
View
   
                                          
  7.
  
    Flynn J, Chan J, Triebold K, Dalton D, Stewart T, Bloom B
    
    . An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993; 178(6):2249-54.
          PMC: 2191274.
    
          DOI: 10.1084/jem.178.6.2249.
    
    
View
   
                                          
  8.
  
    
    
    . Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet. 1974; 2(7875):237-40.
    
    
    
View
   
                                          
  9.
  
    Chan J, Xing Y, Magliozzo R, Bloom B
    
    . Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med. 1992; 175(4):1111-22.
          PMC: 2119182.
    
          DOI: 10.1084/jem.175.4.1111.
    
    
View
   
                                          
  10.
  
    Ramirez-Busby S, Rodwell T, Fink L, Catanzaro D, Jackson R, Pettigrove M
    
    . A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis. Sci Rep. 2017; 7(1):3790.
          PMC: 5476565.
    
          DOI: 10.1038/s41598-017-03452-y.
    
    
View
   
                                          
  11.
  
    Dwivedi V, Gautam S, Beamer G, Stromberg P, Headley C, Turner J
    
    . IL-10 Modulation Increases Pyrazinamide's Antimycobacterial Efficacy against Mycobacterium tuberculosis Infection in Mice. Immunohorizons. 2023; 7(6):412-420.
          PMC: 10580111.
    
          DOI: 10.4049/immunohorizons.2200077.
    
    
View
   
                                          
  12.
  
    Gopal P, Tasneen R, Yee M, Lanoix J, Sarathy J, Rasic G
    
    . In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ACS Infect Dis. 2017; 3(7):492-501.
          PMC: 5514395.
    
          DOI: 10.1021/acsinfecdis.7b00017.
    
    
View
   
                                          
  13.
  
    Nathan C, Murray H, Wiebe M, Rubin B
    
    . Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983; 158(3):670-89.
          PMC: 2187114.
    
          DOI: 10.1084/jem.158.3.670.
    
    
View
   
                                          
  14.
  
    Santucci P, Aylan B, Botella L, Bernard E, Bussi C, Pellegrino E
    
    . Visualizing Pyrazinamide Action by Live Single-Cell Imaging of Phagosome Acidification and Mycobacterium tuberculosis pH Homeostasis. mBio. 2022; 13(2):e0011722.
          PMC: 9040869.
    
          DOI: 10.1128/mbio.00117-22.
    
    
View
   
                                          
  15.
  
    Gopal P, Nartey W, Ragunathan P, Sarathy J, Kaya F, Yee M
    
    . Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD. ACS Infect Dis. 2017; 3(11):807-819.
          PMC: 5734868.
    
          DOI: 10.1021/acsinfecdis.7b00079.
    
    
View
   
                                          
  16.
  
    Boshoff H, Xu X, Tahlan K, Dowd C, Pethe K, Camacho L
    
    . Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem. 2008; 283(28):19329-41.
          PMC: 2443648.
    
          DOI: 10.1074/jbc.M800694200.
    
    
View
   
                                          
  17.
  
    Hu Y, Coates A, Mitchison D
    
    . Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2006; 10(3):317-22.
    
    
    
View
   
                                          
  18.
  
    Lanoix J, Lenaerts A, Nuermberger E
    
    . Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech. 2015; 8(6):603-10.
          PMC: 4457036.
    
          DOI: 10.1242/dmm.019513.
    
    
View
   
                                          
  19.
  
    Lee P, Chan K, Jiang L, Chen T, Li C, Lee T
    
    . Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J. 2008; 27(3):224-30.
    
          DOI: 10.1097/INF.0b013e31815b494c.
    
    
View
   
                                          
  20.
  
    Lamont E, Dillon N, Baughn A
    
    . The Bewildering Antitubercular Action of Pyrazinamide. Microbiol Mol Biol Rev. 2020; 84(2).
          PMC: 7062198.
    
          DOI: 10.1128/MMBR.00070-19.
    
    
View